Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
The development of multiagent vaccines offers the advantage of eliciting protection against multiple diseases with minimal inoculations over a shorter time span. We report here the results of using formulations of individual Venezuelan equine encephalitis (VEE) virus replicon-vectored vaccines against a bacterial disease, anthrax; a viral disease, Marburg fever; and against a toxin-mediated disease, botulism. The individual VEE replicon particles (VRP) expressed mature 83-kDa protective antigen (MAT-PA) from Bacillus anthracis, the glycoprotein (GP) from Marburg virus (MBGV), or the H(C) fragment from botulinum neurotoxin (BoNT H(C)). CBA/J mice inoculated with a mixture of VRP expressing BoNT H(C) serotype C (BoNT/C H(C)) and MAT-PA were 80% protected from a B. anthracis (Sterne strain) challenge and then 100% protected from a sequential BoNT/C challenge. Swiss mice inoculated with individual VRP or with mixtures of VRP vaccines expressing BoNT H(C) serotype A (BoNT/A H(C)), MAT-PA, and MBGV-GP produced antibody responses specific to the corresponding replicon-expressed protein. Combination of the different VRP vaccines did not diminish the antibody responses measured for Swiss mice inoculated with formulations of two or three VRP vaccines as compared to mice that received only one VRP vaccine. Swiss mice inoculated with VRP expressing BoNT/A H(C) alone or in combination with VRP expressing MAT-PA and MBGV GP, were completely protected from a BoNT/A challenge. These studies demonstrate the utility of combining individual VRP vaccines into multiagent formulations for eliciting protective immune responses to various types of diseases.
Lee
John S
JS
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. John.Lee@det.amedd.army.mil
Groebner
Jennifer L
JL
Hadjipanayis
Angela G
AG
Negley
Diane L
DL
Schmaljohn
Alan L
AL
Welkos
Susan L
SL
Smith
Leonard A
LA
Smith
Jonathan F
JF
D000818:Animals; D000881:Anthrax / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000276:immunology*; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis; D001905:Botulinum Toxins / Q000276:immunology*; D036022:Capsid Proteins / Q000276:immunology; D004666:Encephalitis Virus, Venezuelan Equine / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D029024:Marburgvirus / Q000276:immunology*; D051379:Mice; D008808:Mice, Inbred CBA; D009498:Neurotoxins / Q000276:immunology; D012093:Replicon / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D022122:Anthrax Vaccines; D000914:Antibodies, Viral; D036022:Capsid Proteins; D009498:Neurotoxins; D018074:Vaccines, Conjugate; D014765:Viral Vaccines; D001905:Botulinum Toxins